Trial Profile

A Phase 2 Study Evaluating the Efficacy of Anti-CD38 Antibody in Combination With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Nivolumab (Primary) ; TG 01 Targovax (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Pancreatic ductal carcinoma
Focus Therapeutic Use
Acronyms DARANIVOVAX

30 Jun 2026 Status changed from recruiting to active, no longer recruiting.
15 May 2026 Planned End Date changed from 1 Jan 2027 to 1 Jun 2027.
15 May 2026 Planned primary completion date changed from 1 Jan 2026 to 1 Jun 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com